Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mohamed Shanshal

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2024
Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM databaseKaushal Parikh, Anastasios Dimou, Konstantinos Leventakos, et al.
JTO Clinical and Research Reports|May 8, 2025
Combination of Lurbinectedin and Osimertinib for Treatment of <i>EGFR</i>-Mutated Transformed SCLC: A Brief ReportAditi Singh, Arthi Sridhar, Aastha Poddar, et al.
Cancers|March 14, 2026
Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck MalignanciesDaniel Thomas Jones, Rishi Kumar Nanda, Abbas Ali Hussain, et al.
JTO Clinical and Research Reports|November 24, 2025
Safety and Efficacy of Sequential Chemoimmunotherapy Followed by Concurrent Chemoradiation in Unresectable Stage III NSCLCArthi Sridhar, Aditi Singh, Scott Hansen, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2024
Impact of EML4-ALK Variants and Co-Occurring TP53 Mutations on Duration of First-Line ALK Tyrosine Kinase Inhibitor Treatment and Overall Survival in ALK Fusion-Positive NSCLC: Real-World Outcomes From the GuardantINFORM databaseKaushal Parikh, Anastasios Dimou, Konstantinos Leventakos, et al.
JTO Clinical and Research Reports|May 8, 2025
Combination of Lurbinectedin and Osimertinib for Treatment of <i>EGFR</i>-Mutated Transformed SCLC: A Brief ReportAditi Singh, Arthi Sridhar, Aastha Poddar, et al.
Cancers|March 14, 2026
Evaluating Tissue-Agnostic Approvals in Thoracic and Head and Neck MalignanciesDaniel Thomas Jones, Rishi Kumar Nanda, Abbas Ali Hussain, et al.
JTO Clinical and Research Reports|November 24, 2025
Safety and Efficacy of Sequential Chemoimmunotherapy Followed by Concurrent Chemoradiation in Unresectable Stage III NSCLCArthi Sridhar, Aditi Singh, Scott Hansen, et al.
Pageof 2